A carregar...
UGT1A1 Genotype-Dependent Dose Adjustment of Belinostat in Patients With Advanced Cancers Using Population Pharmacokinetic Modeling and Simulation
Belinostat is a second-generation zinc-binding histone deacetylase inhibitor that is approved for peripheral T-cell lymphoma and is currently being studied in small cell lung cancer and other advanced carcinomas as a 48-hour continuous intravenous infusion. Belinostat is predominantly metabolized by...
Na minha lista:
| Publicado no: | J Clin Pharmacol |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6357964/ https://ncbi.nlm.nih.gov/pubmed/26637161 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.627 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|